SION - Sionna Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$27.20
DETAILS
HIGH:
$60.00
LOW:
$5.00
MEDIAN:
$7.00
CONSENSUS:
$27.20
UPSIDE:
414.18%
About Sionna Therapeutics, Inc. (https://www.sionnatx.com)
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Cloonan | President, Chief Executive Officer & Director | 1972 | $1,030,642 USD |
| Elena H. Ridloff | Chief Financial Officer | 1980 | $771,602 USD |
| Caroline Stark Beer | Chief Business Officer | 1979 | $268,113 USD |
| Andy Chu | Vice President of Information & Technology | – | – |
| Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research | – | – |
| Jennifer Fitzpatrick | Chief Legal Officer | 1977 | – |
| Mark Munson | Co-founder & Senior Vice President of Medicinal Chemistry | – | – |
| Meghan Bagshaw | Vice President of Programs, Portfolio & Operations | – | – |
| Sarah J. Spencer | Vice President of Corporate Communications | – | – |
| Vanya Sagar | Chief People Officer | 1976 | – |